Related Experiment Video
Updated: Jul 26, 2026
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report
J A Klem1, J V Schaffer, P D Crane
1Yale University School of Medicine, West Haven VA Medical Center, USA.
Background:
We report a method for detection of deep venous thrombosis with a technetium 99m-labeled peptide (DMP 444). The N-methyl-arginine-glycine-aspartic acid sequence on DMP 444 binds the glycoprotein IIb/IIIa receptor on activated platelets (inhibition constant [IC50] for fibrinogen binding = 6 nmol/L).
Methods:
DMP 444 (23 to 27 mCi) was injected into 11 patients with clinical suspicion of deep venous thrombosis, diagnostic confirmation by ultrasound, and a positive D-dimer test result. Planar images in the anterior and posterior projections were obtained at 10 to 40 minutes, 50 to 80 minutes, and 120 to 150 minutes after injection.
Results:
No clinically significant adverse effects were noted after DMP 444 administration. One patient (excluded from the analysis) withdrew consent, so image acquisition was not complete. By 10 to 40 minutes after injection, 8 of 10 patients demonstrated an area of increased activity that was clearly related to the abnormality noted on ultrasound. Most patients were taking warfarin (Coumadin) and heparin (n = 8) or heparin (n = 1) and warfarin (n = 1) alone at the time of the imaging. The average time from onset of symptoms to injection of DMP 444 was 5 days (range 1 to 18 days).
Conclusion:
These preliminary human studies indicate that DMP 444 is safe and may be of value in the diagnosis of deep venous thrombosis.
Insights
Technetium 99m-labeled peptide DMP 444 shows promise for diagnosing deep venous thrombosis (DVT). Early imaging results in patients with suspected DVT indicate DMP 444 is safe and effective.
Area of Science:
- Radiopharmaceuticals
- Molecular Imaging
- Vascular Medicine
Background:
- Deep venous thrombosis (DVT) diagnosis remains a clinical challenge.
- Activated platelets express glycoprotein IIb/IIIa receptors, potential targets for imaging agents.
- DMP 444 is a novel technetium 99m-labeled peptide targeting these receptors.
Purpose of the Study:
- To evaluate the safety and efficacy of DMP 444 for detecting DVT.
- To assess the diagnostic performance of DMP 444 imaging in patients with suspected DVT.
Main Methods:
- 11 patients with suspected DVT underwent imaging after DMP 444 injection.
- Planar scintigraphic images were acquired at multiple time points post-injection.
- DMP 444 targets glycoprotein IIb/IIIa receptors on activated platelets.
Main Results:
- DMP 444 was well-tolerated with no significant adverse events.
- 8 out of 10 patients showed increased radiotracer uptake correlating with ultrasound findings.
- Abnormalities were visualized as early as 10-40 minutes post-injection.
Conclusions:
- DMP 444 demonstrates safety in preliminary human studies.
- This agent shows potential as a valuable tool for DVT diagnosis.
- Further investigation is warranted to confirm its clinical utility.
Related Concept Videos
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:29Venous Thrombosis III: Interprofessional Care